Making systems glycobiology a reality.
Prof. Pauline Rudd of the National Institute for Bioprocessing Research and Training (NIBRT) in Dublin, Ireland, has developed strategies for changing glycans into clinical markers in the diagnosis and treatment of cancers. This research may one day lead to the development of simple blood tests to diagnose cancers and measure the impact of treatments.
In a collaboration with Waters, Prof. Rudd's research team at NIBRT have developed GlycoBase 3+, the world’s first database for glycan analysis by UPLC. A repository of chromatographic retention positions expressed in glucose units for sets of glycan structures associated with a range of biotherapeutics, the GlycoBase 3+ Database gives biopharmaceutical manufacturers a fast and powerful tool for confirming the structure of various glycosylated proteins. When used during the manufacturing process, GlycoBase 3+ enables biopharmaceutical manufacturers to gain greater control over their manufacturing process, thereby ensuring safety, efficacy and regulatory compliance.
Waters LC/MS technologies is integral to her work. According to Prof. Rudd, now the high throughput and reproducible nature of Waters' ACQUITY UPLC platform is helping to further the rapid, detailed analysis needed for bioprocessing as well the integration of glycomics with other fields, such as proteomics and genomics, thereby making systems glycobiology a reality in both bioprocessing and natural systems.